UnknownPhase 3NCT02620605

The Influence of Timing of Cabergoline Initiation on Prevention of OHSS

Studying Ovarian hyperstimulation syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Mona M Shaban
Principal Investigator: Mona M Shaban, MD
Intervention: Late Cabergoline 0.5mg(drug)
Enrollment: 75 target
Eligibility: 19-35 years · FEMALE
Timeline: 2017 – 2019

Study locations (1)

IVF department in Kasr Alaini hospital,private IVF centre, Cairo, Egypt

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02620605 on ClinicalTrials.gov

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07043322
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
Tanta University

See all trials for Ovarian hyperstimulation syndrome →

← Back to all trials